CSIMarket
 
Arbutus Biopharma Corp  (NASDAQ: ABUS)
Other Ticker:  
 
 
Price: $3.2900 $-0.01 -0.303%
Day's High: $3.36 Week Perf: -1.2 %
Day's Low: $ 3.24 30 Day Perf: 0.3 %
Volume (M): 427 52 Wk High: $ 4.73
Volume (M$): $ 1,404 52 Wk Avg: $3.40
Open: $3.30 52 Wk Low: $2.30



 Market Capitalization (Millions $) 622
 Shares Outstanding (Millions) 189
 Employees 73
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -77
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Arbutus Biopharma Corp
Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is a biotechnology company headquartered in Warminster, Pennsylvania, United States. The company has a focus on developing novel therapeutics that address hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), and other liver diseases.

Their lead product candidate, AB-729, is a potentially first-in-class RNA interference (RNAi) therapeutic targeting HBV surface antigen, with the aim of achieving sustained virologic responses in patients. The drug utilizes Arbutus' proprietary GalNAc delivery technology, which is designed to specifically deliver RNAi agents to hepatocytes, the primary liver cells responsible for HBV replication.

Arbutus Biopharma operates a fully integrated research and development center in Burnaby, British Columbia, Canada, which includes chemistry and bioanalytical laboratories, as well as manufacturing facilities for clinical and commercial production of its drug products. The company has a strong intellectual property portfolio consisting of a variety of patents and patent applications that cover its drug candidates, delivery technologies and manufacturing processes.

The company has collaborations with a number of other biotech and pharmaceutical companies, including Roivant Sciences and Gritstone Oncology, aimed at developing RNAi therapies for the treatment of a variety of diseases. Arbutus also collaborates with the Baruch S Blumberg Institute, a renowned research institute based in Doylestown, Pennsylvania, to discover and develop new drug candidates for the treatment of liver diseases.

Arbutus Biopharma was founded in 2005 and went public in 201 The company is traded on the NASDAQ Global Market under the ticker symbol "ABUS".


   Company Address: 701 Veterans Circle Warminster 18974 PA
   Company Phone Number: 469-0914   Stock Exchange / Ticker: NASDAQ ABUS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -2.94%    
JNJ        1.24% 
LLY   -2.83%    
MRK   -3.92%    
REGN   -2.43%    
VRTX   -2.33%    
• View Complete Report
   



Management Announcement

Arbutus Biopharma on the Cusp of a Breakthrough: A Promising Path Toward a Functional Cure for Chronic Hepatitis B

Published Mon, Jan 13 2025 12:30 PM UTC

Arbutus Biopharma Corporation (Nasdaq: ABUS), a leading figure in the biopharmaceutical landscape, is making...

Clinical Study

Arbutus Biopharma Corporation A Promising Presence in the Fight Against Chronic Hepatitis B and an Upcoming Virtual E...

Published Tue, Nov 26 2024 12:30 PM UTC

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company renowned for its innovative approaches to virology, has announced its participation in the H.C. Wainwright @ Home virtual fireside chat series scheduled for December 3, 2024, at 11:00 AM ET. This engagement is anticipated to be a significant opportunity for the company to share insights ...

Clinical Study

Arbutus Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Published Fri, Nov 15 2024 4:02 PM UTC

Promising Advances in HBV Treatment: Arbutus Imdusiran and Interferon Combine for Transformative Patient Outcomes In recent developments within the realm of hepatitis B virus (HBV) treatment, Arbutus Biopharma s investigational therapeutic, Imdusiran, has demonstrated significant efficacy when combined with a short course of Interferon (IFN). According to data from the Pha...

Clinical Study

Arbutus Pharmaceuticals Arbutus Imdusiran and VTP-300 Combination Therapy Shows Promising Results in Lowering HBsAg ...

Published Thu, Jun 6 2024 3:15 PM UTC

Treatment with Arbutus Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg LevelsData highlighted in oral presentation at the European Association for the Study of the Liver (EASL) CongressArbutus Pharmaceuticals, a leading biopharmaceutical company focused on discovering, developing, and commercializing a cure for patients suffering from chronic hepati...

Clinical Study

Arbutus Imdusiran and Short Course Interferon: A Promising Strategy towards Achieving Sustained Undetectable HBsAg Le...

Published Wed, Jun 5 2024 6:30 AM UTC

In the field of Hepatitis B Virus (HBV) research, one of the major challenges has been achieving sustained undetectable levels of Hepatitis B surface antigen (HBsAg), which is considered a crucial requirement for functional cure. However, a recent study conducted by Arbutus Biopharma Corp presents a potential breakthrough in this area using a combination of Arbutus Imdusiran...







Arbutus Biopharma's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com